Email this article GROWTH PARTICULARS OF PITUITARY MACROADENOMAS WITH VARIOUS HORMONAL ACTIVITIES
- Authors: Ilovayskaya I.A.1, Dreval' A.V.1, Krivosheeva Y.G.1, Astaf'eva L.I.2, Stashuk G.A.1
-
Affiliations:
- Moscow Regional Research and Clinical Institute (MONIKI)
- Burdenko Neurosurgical Institute
- Issue: Vol 44, No 4 (2016)
- Pages: 451-456
- Section: ARTICLES
- URL: https://almclinmed.ru/jour/article/view/434
- DOI: https://doi.org/10.18786/2072-0505-2016-44-4-451-456
- ID: 434
Cite item
Full Text
Abstract
Background: Pituitary adenoma is not as infrequent as thought previously. The prevalence of macroadenomas in general population is up to 0.16–0.2%. Magnetic resonance imaging (MRI) is a method of choice in diagnosis of pituitary adenomas. Until now, specifics of imaging of pituitary adenomas with various hormonal activities have not been discussed.
Aim: To analyze comparatively the size, volumes and growth direction in pituitary macroadenomas with various hormonal activities.
Materials and methods: We analyzed MRI images of 305 patients with hypophyseal adenomas of more than 10 mm diameter, among them with non-functioning adenomas (n=109), prolactinomas (n=58), and somatotropinomas (n=138).
Results: Depending on their hormonal activity, hypophyseal adenomas had different volumes (р<0.001): non-functioning hypophyseal adenomas had the volume of 6620 [2637; 14492] mm3 , prolactinomas – 5365 [1495; 10316] mm3 , somatotropinomas – 3052 [1696; 5727] mm3 . In the majority of patients from all groups, extrasellar growth at several directions was observed. Onedirectional growth was seen in 29% of non-functioning hypophyseal adenomas, 41% of prolactinomas and 37% of somatotropinomas (р>0.05). Non-functioning hypophyseal adenomas and prolactinomas demonstrated mostly suprasellar growth (in 83.5 and 79.3% of cases, respectively), whereas somatotropinomas were growing mostly in infrasellar direction (66.1%).
Conclusion: These characteristic features of hypophyseal macroadenomas with various hormonal activities could be used for differential diagnosis, which may help to optimize patient assessment during the diagnostic work-up.
About the authors
I. A. Ilovayskaya
Moscow Regional Research and Clinical Institute (MONIKI)
Author for correspondence.
Email: irena.ilov@yandex.ru
MD, PhD, Senior Research Fellow, Department of Therapeutic Endocrinology,
61/2–9 Shchepkina ul., Moscow, 129110
Russian FederationA. V. Dreval'
Moscow Regional Research and Clinical Institute (MONIKI)
Email: fake@neicon.ru
MD, PhD, Professor, Head of Department of Therapeutic Endocrinology; Chief of Chair of Endocrinology, Postgraduate Training Faculty,
61/2 Shchepkina ul., Moscow, 129110
Russian FederationYu. G. Krivosheeva
Moscow Regional Research and Clinical Institute (MONIKI)
Email: fake@neicon.ru
MD, Postgraduate Student, Chair of Endocrinology, Postgraduate Training Faculty,
61/2 Shchepkina ul., Moscow, 129110
Russian FederationL. I. Astaf'eva
Burdenko Neurosurgical Institute
Email: fake@neicon.ru
MD, PhD, Leading Research Fellow, Pituitary Tumor Department,
16 4-ya Tverskaya-Yamskaya ul., Moscow, 125047
Russian FederationG. A. Stashuk
Moscow Regional Research and Clinical Institute (MONIKI)
Email: fake@neicon.ru
MD, PhD, Professor, Chief Research Fellow, Department of Roentgenology; Chair of Radiology, Postgraduate Training Faculty,
61/2 Shchepkina ul., Moscow, 129110
Russian FederationReferences
- Karavitaki N. Prevalence and incidence of pituitary adenomas. Ann Endocrinol (Paris). 2012;73(2):79–80. doi: 10.1016/j.ando.2012.03.039.
- Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613–9. doi: 10.1002/cncr.20412.
- Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377–82. doi: 10.1111/j.1365-2265.2009.03667.x.
- Tjörnstrand A, Gunnarsson K, Evert M, Holmberg E, Ragnarsson O, Rosén T, Filipsson Nyström H. The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. Eur J Endocrinol. 2014;171(4):519–26. doi: 10.1530/EJE-14-0144.
- Fernández-Balsells MM, Murad MH, Barwise A, Gallegos-Orozco JF, Paul A, Lane MA, Lampropulos JF, Natividad I, Perestelo-Pérez L, Ponce de León-Lovatón PG, Erwin PJ, Carey J, Montori VM. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011;96(4):905–12. doi: 10.1210/jc.2010-1054.
- Orija IB, Weil RJ, Hamrahian AH. Pituitary incidentaloma. Best Pract Res Clin Endocrinol Metab. 2012;26(1):47–68. doi: 10.1016/j.beem.2011.07.003.
- Famini P, Maya MM, Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab. 2011;96(6):1633–41. doi: 10.1210/jc.2011-0168.
- Дедов ИИ, ред. Клиническая нейроэндокринология. М.: УП Принт; 2001. 343 с.
- Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, Sahnoun M, Brue T, Girard N, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Cotton F, Delemer B, Higel B, Boulin A, Gaillard S, Luca F, Goichot B, Dietemann JL, Beckers A, Bonneville JF. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015;22(2):169–77. doi: 10.1530/ERC-14-0305.
Supplementary files
